ArticleThe Journal of pediatrics2013
Intestinal inflammatory biomarkers and outcome in pediatric Clostridium difficile infections.
Article in The Journal of pediatrics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Systematic Review on the Correlation of Quantitative PCR Cycle Threshold Values of Gastrointestinal Pathogens With Patient Clinical Presentation and Outcomes.Frontiers in medicine · 2021Pooled it
- Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA).Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2018Guideline
- Association between NSAIDs and Clostridium difficile-Associated Diarrhea: A Systematic Review and Meta-Analysis.Canadian journal of gastroenterology & hepatology · 2016Pooled it
- MicroRNA miR-27a-5p Reduces Intestinal Inflammation Induced by Clostridioides difficile Flagella by Regulating the Nuclear Factor-κB Signaling Pathway.The Journal of infectious diseases · 2025Article
- Evaluation of non-invasive diagnostic tools for diarrhea: a systematic review of point-of-care tests and biomarkers.Annals of medicine and surgery (2012) · 2024Review
- An integrated pipeline for prediction of Clostridioides difficile infection.Scientific reports · 2023Article
- A Multifaced Aspect ofJournal of personalized medicine · 2023Review
- Morphological Assessment and Biomarkers of Low-Grade, Chronic Intestinal Inflammation in Production Animals.Animals : an open access journal from MDPI · 2022Review
- Cell-Free Paper-Based Analysis of Gut Microbiota and Host Biomarkers.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Clostridioides difficile Infection in Pediatric Inflammatory Bowel Disease: A Clinician's Dilemma.Journal of the Pediatric Infectious Diseases Society · 2021Article
- Vancomycin Use in Children and Neonates across Three Decades: A Bibliometric Analysis of the Top-Cited Articles.Pathogens (Basel, Switzerland) · 2021Review
- Article
- Probiotics Exhibit Strain-Specific Protective Effects in T84 Cells Challenged WithFrontiers in microbiology · 2021Article
- Leptin Receptor q223r Polymorphism InfluencesFrontiers in cellular and infection microbiology · 2021Article
- Host Diagnostic Biomarkers of Infection in the ICU: Where Are We and Where Are We Going?Current infectious disease reports · 2021Review
- Article
- IL-17-producing γδ T cells protect against Clostridium difficile infection.The Journal of clinical investigation · 2020Article
- Host Immune Markers Distinguish Clostridioides difficile Infection From Asymptomatic Carriage and Non-C. difficile Diarrhea.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020Article
- Colonization of Mice With Amoxicillin-AssociatedFrontiers in microbiology · 2020Article
- Type 3 Immunity during Clostridioides difficile Infection: Too Much of a Good Thing?Infection and immunity · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectivesTo identify specific fecal biomarkers for symptomatic Clostridium difficile infection and predictors of poor outcomes. STUDY
designWe enrolled 65 children with positive C difficile testing (cases) and 37 symptomatic controls. We also analyzed stool samples from colonized and non-colonized asymptomatic children. We performed enzyme immunoassays to determine fecal interleukin (IL)-8, lactoferrin, and phosphorylated-p38 protein concentrations, and quantitative polymerase chain reaction to determine IL-8 and chemokine ligand (CXCL)-5 RNA relative transcript abundances, and C difficile bacterial burden.
resultsOf 68 asymptomatic controls, 16 were colonized with C difficile. Phosphorylated-p38 was specific for C difficile infection but lacked sensitivity. Fecal cytokines were elevated in samples from symptomatic children, whether cases or controls. In children with C difficile infection, fecal CXCL-5 and IL-8 messenger RNA abundances at diagnosis correlated with persistent diarrhea after 5 days of C difficile infection therapy and with treatment with vancomycin. When children with concomitant viral gastroenteritis were excluded, these correlations persisted. Time-to-diarrhea resolution was significantly longer in patients with elevated fecal cytokines at diagnosis. A logistic regression model identified high CXCL-5 messenger RNA abundance as the only predictor of persistent diarrhea. Conversely, fecal C difficile bacterial burden was not different in symptomatic and asymptomatic children and did not correlate with any clinical outcome measure.
conclusionsFecal inflammatory cytokines may be useful in distinguishing C difficile colonization from disease and identifying children with C difficile infection likely to have prolonged diarrhea.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.